| Autor: |
Sargsyan, G. H., Bakhshinyan, V. V., Vardanyan, A. G., Nazanyan, A., Hovhannesyan, N. S., Badalyan, L. G., Shukuryan, A. K. |
| Předmět: |
|
| Zdroj: |
Journal of Hearing Science; 2022, Vol. 12 Issue 1, p157-158, 2p |
| Abstrakt: |
Objective: Platinum-based chemotherapeutic drugs are considered the main treatment for various malignant tumors. The first generation platinum-based chemotherapeutic drug such as cisplatin is widely used among both adults and children often as a drug of choice. However, it is one of the most ototoxic drugs. The purpose of the study is to find out the cisplatin-induced cumulative ototoxicity based on pre-exposure hearing status. Material and methods: First time in Armenia, at Nairi MC, Armenia starting from October 2018, program for monitoring of ototoxicity is implemented for patients receiving chemotherapy. This is taking place in and being funded by Science Committee of Ministry of Education and Science of Armenia. The study included 20 adult patients who were exposed to Cisplatin 3--5 times; the range cumulative dose was 100-650mg. As a study sample each ear was examined individually. One of the patients one ear wasn't included in the study since the patient had initial unilateral hearing loss. As a result 39 ears were examined. The samples were divided into two groups. The first group included the ears (n=25) which hearing status didn't change after the treatment based on the results of the pure-tone audiometry (125--12 kH), while the second group included the ears (n=14) which hearing status altered by at least 15-dB based on the results of the pure-tone audiometry. 20 samples from the first group suffered from mild to moderate, moderate or moderate to profound hearing loss, the rest samples had normal pre-exposure hearing status. 10 samples from the second group had normal pre-exposure hearing status or mild haring loss, the other 4 samples suffered from mild to moderate hearing loss. Results: The ototoxicity of cumulative doses of 350 mg and lower was insignificant compared with pre-exposure hearing status. Hearing loss was found among 3 samples; 2 of them had normal pre-exposure hearing status, 1 of them suffered from pre-exposure hearing loss. The ototoxicity of cumulative doses starting from 400--550 mg was significantly associated with pre-exposure hearing status. Hearing loss was found among 7 samples; only 2 of them suffered from pre-exposure moderate hearing loss, the other 5 had normal pre-exposure hearing status or mild haring loss. 4 samples were exposed to cumulative doses of 600-650 mg. Hearing loss was found among all of them, but 3 of them had normal pre-exposure hearing status, 1 of them suffered from pre-exposure mild to moderate hearing loss. Conclusions: The prediction of the ototoxicity of cumulative doses of 350 mg and lower is insignificantly associated with pre-exposure hearing status. Starting from 400 mg there was a considerable association with pre-exposure hearing status. Parallel to the dose increase, the ototoxicity on ears with normal pre-exposure hearing status is more predictable. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
